Adial pharmaceuticals, inc. (ADIL)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating Expenses:
Research and development expenses

1,054

1,203

864

1,210

686

47

188

76

55

27

57

General and administrative expenses

1,245

886

881

948

1,562

1,042

3,627

1,664

284

160

161

Equity-based compensation

-

-

-

-

-

-

-

-

-

73

22

Total Operating Expenses

2,300

2,090

1,745

2,159

2,249

1,090

3,816

1,741

339

262

241

Loss From Operations

-2,300

-2,090

-1,745

-2,159

-2,249

-1,090

-3,816

-1,741

-339

-262

-241

Other Income (Expense)
Interest income

23

32

29

24

8

-

-

-

-

0

0

Loss on debt extinguishments

-

-

-

-

-

0

-3,496

0

12

0

0

Warrant modification expense

-

0

0

-883

441

-

-

-

-

-

-

Interest and financing charges

-

-

-

-

-

186

878

50

51

30

-

Interest expense

-

-

-

-

-

-

-

-

-

-

22

Total other income (expense)

23

32

29

24

-433

-179

-4,374

-50

-39

-30

-22

Loss Before Provision For Income Taxes

-2,276

-2,058

-1,715

-2,134

-2,682

-1,269

-8,190

-1,792

-378

-292

-264

Benefit from income taxes

-

-

-

-

-

-

-

-

-

0

0

Net Loss

-2,276

-2,058

-1,715

-2,134

-2,682

-1,269

-8,190

-1,792

-378

-292

-264

Net loss per share, basic and diluted

-0.22

-0.16

-0.17

-0.21

-0.33

-0.34

-1.48

-0.50

-0.12

-0.09

-0.08

Weighted average shares, basic and diluted

10,497

10,683

10,252

10,223

8,250

6,665

5,546

3,557

3,268

3,267

3,267